sm-346 and Hyperphagia

sm-346 has been researched along with Hyperphagia* in 1 studies

Other Studies

1 other study(ies) available for sm-346 and Hyperphagia

Article	Year
Antidiabetic Activity of Afobazole in Wistar Rats. Bulletin of experimental biology and medicine, 2018, Volume: 165, Issue:5 Using the streptozotocin model of type 2 diabetes mellitus in Wistar rats, we compared antidiabetic activity of anxiolytic Afobazole with that of metformin. Afobazole in a dose of 10 mg/kg reduced streptozotocin-induced hyperglycemia and polyphagia and prevented accumulation of malonic dialdehyde, being not inferior to metformin in a dose of 300 mg/kg, and was even more effective than metformin in body weight recovery, elimination of polydipsia, and preservation of these effects after treatment withdrawal. Topics: Animals; Anti-Anxiety Agents; Benzimidazoles; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Repositioning; Hyperglycemia; Hyperphagia; Hypoglycemic Agents; Male; Metformin; Morpholines; Rats; Rats, Wistar; Streptozocin	2018

Article

Year

Antidiabetic Activity of Afobazole in Wistar Rats.

Bulletin of experimental biology and medicine, 2018, Volume: 165, Issue:5

Using the streptozotocin model of type 2 diabetes mellitus in Wistar rats, we compared antidiabetic activity of anxiolytic Afobazole with that of metformin. Afobazole in a dose of 10 mg/kg reduced streptozotocin-induced hyperglycemia and polyphagia and prevented accumulation of malonic dialdehyde, being not inferior to metformin in a dose of 300 mg/kg, and was even more effective than metformin in body weight recovery, elimination of polydipsia, and preservation of these effects after treatment withdrawal.

Topics: Animals; Anti-Anxiety Agents; Benzimidazoles; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Repositioning; Hyperglycemia; Hyperphagia; Hypoglycemic Agents; Male; Metformin; Morpholines; Rats; Rats, Wistar; Streptozocin

2018